CONTACT US:
Tel: 0086-20-32721827
32721837
Fax:
0086-20-32721857
export@top-inflatables.com
info@top-inflatables.com
Inflatable
Old drug use new spectrum of new chapter
In the United States FDA approval of new drugs, about 70% to 80% has approved a new drug formulations and new uses, which is old by the new drug.
In fact, the old have used the new drug is no secret that many characteristics of drug companies is to this model to successfully raise funds, or with large pharmaceutical companies to reach agreement. New drugs used in the old classic case, not only revive the reaction stopped, but also of drugs for the Po, Guweijinyong of arsenic, of oxaliplatin……
In today's pharmaceutical companies Inflatable Obstacles generally lack the portfolio of new drugs and embarrassing situation, how to make use of old drugs, many pharmaceutical companies and researchers are constantly exploring one of the hot spots. Old with the new drug is promising: old drugs can explore new clinical indications, but also from the failure to find an opportunity in the old drug. Valuable is the same: the lack of medicine under the old and disadvantages in the clinical application of the formulations on the basis of upgrading, or to change the dosage and administration, the effect of drugs better, more secure.
Most of the giant drug through the development of new clinical indications created by the sales performance also rely on the support of a variety of indications, thus leading pharmaceutical companies for the development of new indications of drug attaches great importance to and invest and spend lots of money Crack troops.
Old with the new drug is not specific to the pharmaceutical research and development of tools, it also features the pharmaceutical companies prefer to make money platform. Many characteristics with the old drugs is that pharmaceutical companies use new, making the original has been neglected or abandoned the original drug-Fang Guangmang. Debiao oxaliplatin group of drug and Cephalon's Provigil has been to give up all the old drugs, the results are made more than 1 billion or even billions of dollars of blockbuster drugs.
The failure rate of new drug development, at least in more than 80 percent, from an accumulation of thousands of abandoned projects constitute a failure of the so-called drug "death library."
"The death" in the death of new drugs or new drug old gathered a great "energy." There are many drug safety and efficacy is more Inflatable Obstacles certain, because only a small number of patients with drug genomic differences, the metabolism of the drug absorbed more sensitive or special, resulting in serious adverse reactions or even death.
And in addition to numerous clinical trials were late because of security factors "shot" of prospective new drugs, there are many well-known drugs such as Vioxx, Rezulin (troglitazone), and so on billions of dollars in sales of blockbuster drugs, listed a number of years after It was dismantling the city.
Perhaps one day, drug breakthroughs in genomics with personalized medical means, through more accurate screening of patients, who can rule out the susceptible population, and strictly medication dosage and time, the loss of the old drug ring the past or have not yet listed Was Darulenggong drug will regain the prospective freshmen.
Past the old with the new drug, most doctors rely on the accidental discovery of (In this sense, medicine label for the promotion and use is not blocked), the next old with the new drug may need to rely more on new technology And new methods, such as CombinatoRx companies with unique in vitro screening technology platform, in the short term on the discovery of a previously unknown series of new clinical indications of drug combinations. Similarly, the transformation of the continuous development of medicine, new drug Inflatable Obstacles development and clinical indications choices become more targeted.
Recently, the European FDA approval of Celgene's EMEA THALOMID for the treatment of newly diagnosed multiple myeloma. Just in the last two weeks, Australia Yaozhengguanli sector TGA formally approved THALOMID for the treatment of bone dysplasia and myeloma. TGA has approved the drug in 2003 for the failure of standard treatment of multiple myeloma patients in the United States FDA on May 25, 2006 with the approval of the drug dexamethasone drug for the treatment of newly diagnosed multiple Inflatable Obstacles myeloma patients. String of market access, to several hundred thousand patients worldwide bring new treatment and rehabilitation opportunities.
And to withdraw from the market THALOMID is the famous old medicine "Thalidomide." What is the magic of thalidomide to make access to medicines regulatory departments and the medical profession and attach great importance to take seriously »
china inflatableIn fact, the old have used the new drug is no secret that many characteristics of drug companies is to this model to successfully raise funds, or with large pharmaceutical companies to reach agreement. New drugs used in the old classic case, not only revive the reaction stopped, but also of drugs for the Po, Guweijinyong of arsenic, of oxaliplatin……
In today's pharmaceutical companies Inflatable Obstacles generally lack the portfolio of new drugs and embarrassing situation, how to make use of old drugs, many pharmaceutical companies and researchers are constantly exploring one of the hot spots. Old with the new drug is promising: old drugs can explore new clinical indications, but also from the failure to find an opportunity in the old drug. Valuable is the same: the lack of medicine under the old and disadvantages in the clinical application of the formulations on the basis of upgrading, or to change the dosage and administration, the effect of drugs better, more secure.
Most of the giant drug through the development of new clinical indications created by the sales performance also rely on the support of a variety of indications, thus leading pharmaceutical companies for the development of new indications of drug attaches great importance to and invest and spend lots of money Crack troops.
Old with the new drug is not specific to the pharmaceutical research and development of tools, it also features the pharmaceutical companies prefer to make money platform. Many characteristics with the old drugs is that pharmaceutical companies use new, making the original has been neglected or abandoned the original drug-Fang Guangmang. Debiao oxaliplatin group of drug and Cephalon's Provigil has been to give up all the old drugs, the results are made more than 1 billion or even billions of dollars of blockbuster drugs.
The failure rate of new drug development, at least in more than 80 percent, from an accumulation of thousands of abandoned projects constitute a failure of the so-called drug "death library."
"The death" in the death of new drugs or new drug old gathered a great "energy." There are many drug safety and efficacy is more Inflatable Obstacles certain, because only a small number of patients with drug genomic differences, the metabolism of the drug absorbed more sensitive or special, resulting in serious adverse reactions or even death.
And in addition to numerous clinical trials were late because of security factors "shot" of prospective new drugs, there are many well-known drugs such as Vioxx, Rezulin (troglitazone), and so on billions of dollars in sales of blockbuster drugs, listed a number of years after It was dismantling the city.
Perhaps one day, drug breakthroughs in genomics with personalized medical means, through more accurate screening of patients, who can rule out the susceptible population, and strictly medication dosage and time, the loss of the old drug ring the past or have not yet listed Was Darulenggong drug will regain the prospective freshmen.
Past the old with the new drug, most doctors rely on the accidental discovery of (In this sense, medicine label for the promotion and use is not blocked), the next old with the new drug may need to rely more on new technology And new methods, such as CombinatoRx companies with unique in vitro screening technology platform, in the short term on the discovery of a previously unknown series of new clinical indications of drug combinations. Similarly, the transformation of the continuous development of medicine, new drug Inflatable Obstacles development and clinical indications choices become more targeted.
Recently, the European FDA approval of Celgene's EMEA THALOMID for the treatment of newly diagnosed multiple myeloma. Just in the last two weeks, Australia Yaozhengguanli sector TGA formally approved THALOMID for the treatment of bone dysplasia and myeloma. TGA has approved the drug in 2003 for the failure of standard treatment of multiple myeloma patients in the United States FDA on May 25, 2006 with the approval of the drug dexamethasone drug for the treatment of newly diagnosed multiple Inflatable Obstacles myeloma patients. String of market access, to several hundred thousand patients worldwide bring new treatment and rehabilitation opportunities.
And to withdraw from the market THALOMID is the famous old medicine "Thalidomide." What is the magic of thalidomide to make access to medicines regulatory departments and the medical profession and attach great importance to take seriously »
Tel: 0086-20-32721827 / 32721837 Fax: 0086-20-32721857
E-mail: export@top-inflatables.com / info@top-inflatables.com
Copyright ©2006-2008 TOP INFLATABLES INC All rights reserved
E-mail: export@top-inflatables.com / info@top-inflatables.com
Copyright ©2006-2008 TOP INFLATABLES INC All rights reserved